知镜 Cognispect · 医学文献与研究工作台

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Nguyen TP, Suzuki S, Okamoto K, Ito R, Mizuno H, Fujita S, Kouketsu T, Teshima K, Sawatsubashi S, Takemoto T, Yamakoshi H, Takahashi M, Kuroda M, Sasano Y, Yoshizaki Y, Matsumoto Y, Ohsawa K, Kudo G, Hirokawa T, Kato S, Konno T, Doi T, Iwabuchi Y, Sugawara A, Yokoyama A.
Proceedings of the National Academy of Sciences of the United States of America · 2026-11-13 · PMID 43024666

文献摘要

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potential causal driver. A chemical screen based on ChREBP transcriptional activity identified D-532 as a small-molecule inhibitor that is effective in human and rodent cells. Oral administration of D-532 protected multiple diabetic mouse models from DKD progression and suppressed ChREBP and its downstream targets, including genes associated with excessive reactive oxygen species production. These findings position ChREBP as a pharmacologically targetable transcriptional driver of DKD and provide proof of concept that ChREBP inhibition can confer renal protection.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。